Microbix Biosystems Inc
TSX:MBX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Shinfox Energy Co Ltd
TWSE:6806
|
TW |
Microbix Biosystems Inc
Research & Development
Microbix Biosystems Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Microbix Biosystems Inc
TSX:MBX
|
Research & Development
-CA$2.3m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-6%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Research & Development
-CA$11.1m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-125%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Research & Development
-$32.5m
|
CAGR 3-Years
10%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-7%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Research & Development
-$300.9m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
-35%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Research & Development
-CA$19m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-86%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Research & Development
-$94.5m
|
CAGR 3-Years
-83%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Microbix Biosystems Inc
Glance View
Microbix Biosystems, Inc. engages in developing and commercializing proprietary biological and technology solutions for human health and wellbeing. The company is headquartered in Mississauga, Ontario. The firm manufactures a range of biological materials for the diagnostics industry, notably antigens (Antigen business) used in immunoassays and its quality assessment and proficiency testing controls (QAPs business). The firm operates in two segments: the development, manufacturing, and sales of antigens as materials for the medical diagnostic industry or as quality assessment products (as finished products) and viral transport medium (VTM) and the development and commercialization of products or technologies such as Kinlytic and . The Kinlyti urokinase, which is a biologic thrombolytic drug used to treat blood clots. The firm's catalogue of catalogue covers a range of pathogens that are implicated in maternal, pediatric, childhood, respiratory, sexually transmitted and insect-borne diseases. Its QAPs are available in over 30 countries.
See Also
What is Microbix Biosystems Inc's Research & Development?
Research & Development
-2.3m
CAD
Based on the financial report for Dec 31, 2025, Microbix Biosystems Inc's Research & Development amounts to -2.3m CAD.
What is Microbix Biosystems Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-6%
Over the last year, the Research & Development growth was -2%. The average annual Research & Development growth rates for Microbix Biosystems Inc have been -9% over the past three years , -19% over the past five years , and -6% over the past ten years .
